In 2025, BGI Group introduced a new wave of technologies, contributing to progress in genomics, cell omics, and spatiotemporal omics. Our efforts are focused on advancing life science exploration and working toward a future where genomics becomes more accessible to everyone.
BGI’s 2025 breakthroughs include Stereo-cell, Stereo-seq V2, as well as Genos, the world’s first multi-billion-parameter open-source Human-Centric genomic foundation model. Together, these tools decode the source code of life, creating a powerful new infrastructure for clinical breakthroughs and precision medicine.
Learn more:
Read
Read
Read
Leveraging its world-leading core technologies, BGI Group made significant advances across multiple research frontiers in 2025, including brain science, regeneration, embryonic development, and plant/animal studies. Landmark studies were published in top-tier international journals, covering mesoscopic brain mapping research, mouse ear regeneration mechanisms, a 3D panoramic atlas of Drosophila development, and deep-sea life science.
In 2025 alone, BGI published 487 papers, including 111 ‘CNNS’ (the leading academic journals Cell, Nature, New England Journal of Medicine, Science, and their related publications, if any) articles, with 21 published in flagship journals.
As of December 31, 2025, BGI has published a total of 5,928 papers, including 880 ‘CNNS’ articles, with 186 published in flagship journals.
BGI has ranked first in the Nature Index for life sciences industrial organizations in the Asia-Pacific region for 10 consecutive years. Additionally, BGI researchers have been recognized as Clarivate’s Highly Cited Researchers for 11 consecutive years, underscoring the global impact.
Learn more:
BGI Group's relentless scientific breakthroughs and robust research output consistently provide the essential technical foundation and scientific consensus crucial for developing new industry standards. In 2025, BGI helped draft and launch 42 standards, including the first ISO Standard for Deep-Sea Biological Materials.
To date, BGI has initiated or co-developed 424 standards, including 9 international standards. These influential guidelines extend across critical domains such as birth defect prevention and control, precision oncology, life science tools, gene synthesis and editing, and agriculture.
Learn more:
Precision Health for Communities
BGI Group is dedicated to delivering precision health to communities. This commitment drives the implementation of impactful public welfare projects, encompassing comprehensive programs including cancer prevention and control, and health awareness campaigns. These efforts are designed to effectively reduce the incidence various cancers, ensuring that cutting-edge genetic technologies empower communities.
To date, BGI has launched over 120 public welfare projects. These initiatives span critical health areas, including non-invasive prenatal genetic testing, genetic screening for thalassemia and hereditary hearing loss, and essential screenings for cervical and colorectal cancers. Cumulatively, these programs have delivered over 30 million screenings.
The HGI-001 injection, which has shown remarkable efficacy for patients with transfusion-dependent β-thalassemia. In April, it secured clinical trial approval from the Thai Food and Drug Administration (ThaiFDA), marking it as China's first hematopoietic stem cell gene therapy product to advance into clinical stages overseas, with its first overseas production line already established in Thailand.
Beyond therapeutics, BGI's diagnostic and surveillance capabilities are also making critical impacts. The CycloneSEQ nanopore sequencing platform, integrated with advanced clinical identification and viral detection systems, has been successfully deployed in the fight against Chikungunya fever. This powerful combination empowers public health authorities and customs agencies across various regions to rapidly decipher the complete viral landscape, bolstering their response efforts.
Learn more:
Read
Green Agriculture for a Sustainable Future
BGI Group remains deeply committed to advancing the agricultural sector. BGI is dedicated to powering agricultural evolution with cutting-edge science, ensuring high-quality and sustainable development.
In 2025, BGI achieved significant breakthroughs in areas such as perennial crop breeding and microbial inoculant development. Crucially, multiple core technologies from these advancements have successfully transitioned into large-scale, real-world applications.
Among these, the Perennial Rice program continues to demonstrate its transformative impact on livelihoods and agricultural sustainability. Currently, it has been promoted across over 100,000 mu (approx. 16,500 acres) in more than 130 demonstration sites across 10 countries, making a tangible contribution to both food security and sustainable agricultural practices.
Furthermore, BGI's microbial inoculants saw remarkable adoption, deployed across over 500,000 mu (approximately 82,000 acres) in their inaugural year. This initiative leverages advanced biotechnology to enable precision fertilization and vital black soil conservation, fostering healthier ecosystems and higher yields.
Learn more:
Education & Science Outreach
Leveraging its unique integrated industry-academia-research model, BGI Group consistently cultivates innovative talent for the life sciences sector. Concurrently, it proactively develops engaging science communication initiatives, thereby strengthening the foundational pillars of scientific education.
In 2025 alone, BGI's joint training programs enrolled 1,410 students, including international students from 16 countries and regions. To date, these co-trained students have cumulatively authored or co-authored an impressive 132 high-quality articles, including 46 in ‘CNNS’ journals. Their contributions also extend to 56 invention patents and 33 software copyrights, showcasing their significant innovative capacity.
In the public science outreach efforts, BGI actively launched the 'BGI Life Science Festival' initiative. Throughout the year, this program reached over 15,000 individuals across 53 schools, encompassing all educational levels from primary to university. Furthermore, BGI has forged partnerships with numerous universities, establishing joint master's and doctoral training programs, fostering top-tier innovative talent.
Learn more:
Commitment to Public Benefit
BGI Group consistently acts on its foundational commitment through numerous compassionate initiatives. BGI harnessed the power of technology to safeguard the hope of life, one act of kindness at a time.
The Mammoth Foundation has supported over 20 thalassemia patients with matching screenings, blood transfusions, iron chelation therapy, and transplant preparations.
The ALS research project has received personal donations exceeding 2 million RMB from BGI Group CEO Yin Ye.
Learn more:
In 2025, BGI Group significantly expanded the consumer-facing portfolio, developing a suite of innovative applications designed to bring cutting-edge science directly to individuals. Through events like the health & wellness partner summit and its inaugural public open day, BGI is actively transforming sophisticated frontier technologies and research breakthroughs into accessible, user-friendly consumer products. This initiative directly addresses the public's growing aspirations for beauty, health, longevity, and intelligence.
- Introduced a multi-omics health management system, shifting the focus of health management from 'treating illness' to 'preventing disease before it manifests'.
- Released rapid genetic testing kits compatible with various daily consumables like alcohol and coffee, seamlessly integrating genetic insights into everyday life.
- Launched an AI service for personal immune care, which quantifies immune aging status to enable more precise health interventions.
- Developed and launched the skincare product line, quickly gaining significant market traction shortly after its debut.
- Pioneered the application of genetic technology in the pet sector through new offerings like pet genetic testing and a unique service that transforms genetic material from beloved pets into memorial diamonds.
- Unveiled the world's first personalized probiotic solution, enabling 'one-person, one-formula' precision management for gut health.
- The BGI-College introduced a life science knowledge platform featuring premium programs such as 'International High-end Study Tours,' 'Gene Magic Cube,' and the 'Master Plan X BGI-College' series.
- BGI launched a range of products adhering to 'BGI Food Standards,' ensuring superior safety and quality from farm to table.
In 2025, BGI Group significantly intensified its global engagement, fostering international partnerships and driving collaborative innovation to collectively explore the frontiers of life science.
International Exchange & Global Outreach
BGI Group Chairman and Co-founder, Wang Jian, undertook a series of visits to countries including Pakistan, Thailand, Indonesia, Nepal, Kenya, and Saudi Arabia. These high-level engagements were crucial for deeply understanding local needs and cultivating international cooperation across various sectors. Concurrently, BGI hosted esteemed delegations from government bodies in Thailand and Pakistan, as well as representatives from the United Nations Food and Agriculture Organization (FAO). These visits facilitated in-depth discussions and strengthened collaborative efforts on key issues such as technical cooperation and industry development.
Learn more:
Read
Read
The ICG-20 Conference
In October, the 20th International Conference on Genomics (ICG-20) returned to Hangzhou, its foundational home. Embodying the pioneering spirit of the Human Genome Project "Owned by All, Done by All, Shared by All", the conference convened over a hundred distinguished guests from 19 countries and regions to explore "The Future of Omics and AI".
Learn more:
Read
Building Partnerships for Shared Success
In 2025, BGI Group initiated and established several international big-science initiatives and alliances to foster collaborative innovation. These include the Southeast Asian Alliance for the Prevention and Treatment of Thalassemia, the Global Consortium to Advance Brain Mapping, and the Wheat Spatiotemporal Atlas Project. Through these multinational collaborations, BGI is dedicating to build a global network for disease prevention and control.
Through local partnerships, BGI has extended its community health services in several countries. In Brunei, it provides nationwide cervical cancer screening for women of screening age. In Indonesia, prenatal screening is offered to expectant mothers. Meanwhile in Saudi Arabia, Through its joint venture Genalive in Saudi Arabia, BGI was awarded a significant contract to deliver comprehensive, outsourced testing services. This partnership supports the nationwide 83 public hospital systems and helps advance the country’s precision medicine capabilities.
Learn more:
In 2025, BGI Group received prestigious awards and honors spanning technological innovation, public welfare, and social responsibility. Each accolade serves as a testament to its core vision of “Science and Technology for the Benefit of Humanity”. Standout acknowledgments include:
- Selection for the 2025 Fortune China Tech 50 list.
- Inclusion of two BGI led international projects in the UN's “International Decade of Sciences for Sustainable Development” global solutions repository, among other prestigious recognitions.
Learn more:
